Arbutus Biopharma Corp Impairment of Intangible Assets (Excluding Goodwill)
Arbutus Biopharma Corp (ABUS) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2021-03-04
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for the quarter ending 2020-12-31 was $0.00.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for the quarter ending 2019-12-31 was $0.00.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for the quarter ending 2019-09-30 was $43.84M, a 195.97% increase year-over-year.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for fiscal 2019 was $43.84M, a 195.97% increase from fiscal 2018.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for fiscal 2018 was $14.81M, a 63.70% decline from fiscal 2017.
- Arbutus Biopharma Corp impairment of intangible assets (excluding goodwill) for fiscal 2017 was $40.80M, a 83.89% decline from fiscal 2016.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $0.00 10-K · filed 2021-03-04 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $43.84M derived: sum of 2 quarters · filed 2021-03-04 | $43.84M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $43.84M 10-Q · filed 2020-11-05 | $43.84M 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $14.81M derived: sum of 2 quarters · filed 2020-03-05 | $14.81M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $14.81M 10-Q · filed 2019-11-06 | $14.81M 10-Q · filed 2019-11-06 | ||
| 2017-12-31 | $40.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $40.80M derived: sum of 2 quarters · filed 2019-03-07 | $40.80M derived: sum of 3 quarters · filed 2019-03-07 | $40.80M 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||
| 2016-12-31 | $96.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $96.87M derived: sum of 2 quarters · filed 2018-03-16 | $253.20M derived: sum of 3 quarters · filed 2018-03-16 | $253.20M 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | $156.32M derived: sum of 2 quarters · filed 2017-11-02 | $156.32M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $156.32M 10-Q · filed 2017-08-03 | $156.32M 10-Q · filed 2017-08-03 | ||
| 2015-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $39.01M derived: sum of 2 quarters · filed 2018-03-16 | $39.01M derived: sum of 3 quarters · filed 2018-03-16 | $39.01M 10-K · filed 2018-03-16 |
| 2015-09-30 | $37.99M 10-Q · filed 2016-11-03 | $37.99M derived: sum of 2 quarters · filed 2016-11-03 | $37.99M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $0.00 derived: sum of 2 quarters · filed 2017-03-22 | $0.00 10-K · filed 2017-03-22 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |